Drug Database
Back to search

France· FR:64535001

LACOSAMIDE ZYDUS 50 mg, comprimé pelliculé

A lacosamide product containing lacosamide, registered in France by ZYDUS FRANCE, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC N03AX18

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedLACOSAMIDE ZYDUS 50 mg, comprimé pell…ATCN03AX18REGISTER NO.FR:64535001PACKS LISTED2CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lacosamideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lacosamide is registered in 18 of 19 countries.

Countries holding a registration under ATC N03AX18 (lacosamide), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 10 of them publish a price we can compare per daily dose
Search lacosamide products by name

Lacosamide · ATC N03AX18

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lacosamide costs, country by country.

Normalised to the WHO defined daily dose (0.3 g), the median price runs from $0.48 in United States to $3.11 in Switzerland — a ×6.4 gap.

  • France: $1.49 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Lacosamide · price per daily dose (0.3 g)

USD · FX 28 Sept 2026

  • CH Switzerland$3.11
  • IT Italy$3.06
  • FR France$1.49
  • US United States$0.48 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
LACOSAMIDE
Manufacturer
ZYDUS FRANCE
Country
France (FR)
ATC code
N03AX18
ATC class
Lacosamide
Defined daily dose
0.3 g, O
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 2

2 priced
  • cip13
    3400930249994
    plaquette(s) PVC PVDC aluminium de 14 comprimé(s)
    EUR 3.26
  • cip13
    3400930250006
    plaquette(s) PVC PVDC aluminium de 56 comprimé(s)
    EUR 12.35

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

62 interactions on record for lacosamide.

Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lacosamide against other medicinesHow interaction checks work

Lacosamide · interactions on record

62 records

  • 5 severe
  • 32 moderate

Most severe, free to view

  • DolasetronA04AA04severe
  • CeritinibL01ED02severe
  • CeritinibL01XE28severe
  • SiponimodL04AA42severe

25 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lacosamide in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lacosamide products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Lacopat, Lacopat Packung Zur Behandlungseinleitung
  • Belgium · Lacosamid Hikma, Lacosamide Eg
  • Bulgaria · Канилад, Лакозамид Гриндекс
  • Cyprus · Kanilad, Lacosadel
  • Czechia · Arkvimma, Kanilad
  • Germany · Kanilad, Lackepila
  • Denmark · 200 mg, Lacosamid Opko Health Spain
  • Estonia · Kanilad, Lacosamide Alembic
  • Spain · Balmid, Kanilad
  • Finland · Lacosamide Fresenius Kabi, Lacosamide Grindeks
  • United Kingdom (Northern Ireland) · Lacosamide, Lacosamide Amarox
  • Greece · Anlamyl, Josamec
  • Croatia · Kanilad, Lacosamide Grindeks
  • Hungary · Anlamyl, Arkvimma
  • Ireland · Lacosamide Ascend, Lacosamide Fresenius Kabi
  • Iceland · Josamec, Lacosamide Accord
  • Italy · Lacosamide Aurobindo, Lacosamide Doc
  • Liechtenstein · Lacosamid Fresenius Kabi, Lacosamide Accord
  • Lithuania · Lacosamide Fresenius Kabi, Lacosamide Grindeks
  • Luxembourg · Lacosamide Eg
  • Latvia · Kanilad, Lacosamide Fresenius Kabi
  • Malta · Anlamyl, Kanilad
  • Netherlands · Cosim, Lacosamide Amarox
  • Norway · Lacosamide Accord, Lacosamide Fresenius Kabi
  • Poland · Arkvimma, Epilantin
  • Portugal · Lacosamida Alter, Lacosamida Aristo
  • Romania · Lacosamidă Teva
  • Sweden · Lacomed, Lacosamide 1a Farma
  • Slovenia · Lacosabil, Lacosamide Grindeks
  • Slovakia · Arkvimma, Kanilad

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e6f421f6-dd08-4496-8398-6a39785b61bb
GET /v1/drugs/e6f421f6-dd08-4496-8398-6a39785b61bb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "64535001",
  "date_amm": "2022-03-24",
  "type_amm": "Procédure nationale",
  "numero_ue": null,
  "substance": "LACOSAMIDE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "comprimé pelliculé",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about lacosamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console